Kristin Stafford was named Chief Financial Officer of Zymeworks Inc., succeeding Kenneth Galbraith. As of November 6, 2026, Zymeworks Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 1, 2026, naming 1 appointment and 1 departure (Form 8-K, April 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Zymeworks Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Zymeworks Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-01. It names 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Zymeworks Inc. files it.
Also on the record for Zymeworks Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by Rubric Capital Management LP | 9.49% of the class | 5%+ stakes | Source |
| April 15, 2026 | Stake report, Schedule 13G, by Perceptive Advisors LLC | 5.4% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Rubric Capital Management LP | 7.68% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Morgan Stanley | 3.4% of the class | 5%+ stakes | Source |
| November 19, 2025 | Stake report, Schedule 13D/A, by EcoR1 Capital, LLC | 30.7% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 5.2% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Redmile Group, LLC | 4.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Redmile Group, LLC | 5.6% of the class | 5%+ stakes | Source |
| July 16, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Zymeworks Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Zymeworks Inc. and the records around it.
Zymeworks Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
Watch Zymeworks Inc.
Get an email when Zymeworks Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zymeworks Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Zymeworks Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zymeworks Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-01 | In | Chief Financial Officer | 8-K, 2026-04-01 | ||
| 2026-04-01 | Out | Chief Financial Officer | 8-K, 2026-04-01 |
Who leads Zymeworks Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Kristin Stafford, appointed (filed 2026-04-01).
New leaders reset buying decisions — get the Full Report on Zymeworks Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Zymeworks Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Zymeworks Inc.Every change, in the filing's words
Appointed: Kristin Stafford, Chief Financial Officer
On March 31, 2026, Zymeworks Inc. (the "Company") appointed Ms. Kristin Stafford, age 44, as Executive Vice President, Chief Financial Officer of the Company, effective upon her commencement of employment with the Company on April 1, 2026 (the "Start Date").
Departing: Kenneth Galbraith, Chief Financial Officer
In connection with Ms. Stafford's appointment and effective as of the Start Date, Mr. Kenneth Galbraith ceased serving as interim Chief Financial Officer, principal financial officer and principal accounting officer of the Company.
- Effective as of the Start Date, Ms. Stafford has assumed the duties of the Company's principal financial officer and principal accounting officer.
- Prior to joining the Company, Ms. Stafford served as Senior Vice President, Chief Accounting Officer for Royalty Pharma plc, since December 2018.
- Prior to this position, she served as Vice President, Finance of Royalty Pharma and Chief Financial Officer of BioPharma Credit plc, an affiliate of Royal Pharma, from 2016 to 2018.
- Previously, Ms. Stafford was a director at Ernst & Young LLP Capital Markets in London, specializing in U.S. transactions involving European life sciences companies.
- She also previously managed the external SEC reporting for iHeartMedia and was an auditor at Deloitte.
- Ms. Stafford is currently a board member at NovoCure Limited.
- She is a CPA and holds a B.Sc. degree in business administration from Sonoma State University.
- The Employment Agreement does not have a specific term.
- Pursuant to the Employment Agreement, Ms. Stafford is entitled to the following compensation and benefits: An annual base salary of $520,000, with eligibility to earn an annual discretionary bonus of an initial amount of up to 45% of her annual base salary, including for 2026, based upon the achievement of certain Company goals determined by the Company.
- A signing bonus of $52,000 to be paid on the first scheduled pay day following the Start Date.
Tools for this story
Each opens in a new tab, filled in for Zymeworks Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.